

# Christian Kellner

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3622688/publications.pdf>

Version: 2024-02-01

93  
papers

2,239  
citations

186265

28  
h-index

243625

44  
g-index

95  
all docs

95  
docs citations

95  
times ranked

2416  
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel Bispecific Antibodies Increase $\gamma\delta$ T-Cell Cytotoxicity against Pancreatic Cancer Cells. <i>Cancer Research</i> , 2014, 74, 1349-1360.	0.9	133
2	A recombinant trispecific single-chain Fv derivative directed against CD123 and CD33 mediates effective elimination of acute myeloid leukaemia cells by dual targeting. <i>British Journal of Haematology</i> , 2010, 150, 574-586.	2.5	115
3	Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation. <i>Blood</i> , 2010, 116, 2277-2285.	1.4	111
4	Modulating Cytotoxic Effector Functions by Fc Engineering to Improve Cancer Therapy. <i>Transfusion Medicine and Hemotherapy</i> , 2017, 44, 327-336.	1.6	87
5	Tribody [(HER2) $\times$ CD16] Is More Effective Than Trastuzumab in Enhancing $\gamma\delta$ T Cell and Natural Killer Cell Cytotoxicity Against HER2-Expressing Cancer Cells. <i>Frontiers in Immunology</i> , 2018, 9, 814.	4.8	84
6	A Novel CD19-directed Recombinant Bispecific Antibody Derivative With Enhanced Immune Effector Functions for Human Leukemic Cells. <i>Journal of Immunotherapy</i> , 2008, 31, 871-884.	2.4	75
7	Selective induction of apoptosis in leukemic B-lymphoid cells by a CD19-specific TRAIL fusion protein. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 233-246.	4.2	73
8	Effective Elimination of Acute Myeloid Leukemic Cells by Recombinant Bispecific Antibody Derivatives Directed Against CD33 and CD16. <i>Journal of Immunotherapy</i> , 2010, 33, 599-608.	2.4	73
9	Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. <i>British Journal of Haematology</i> , 2010, 148, 879-889.	2.5	63
10	Impact of Epidermal Growth Factor Receptor (EGFR) Cell Surface Expression Levels on Effector Mechanisms of EGFR Antibodies. <i>Journal of Immunology</i> , 2012, 189, 5230-5239.	0.8	59
11	The novel tribody [(CD20) $\times$ CD16] efficiently triggers effector cell-mediated lysis of malignant B cells. <i>Leukemia</i> , 2013, 27, 190-201.	7.2	58
12	An Anti-EGFR IgA That Displays Improved Pharmacokinetics and Myeloid Effector Cell Engagement <i>In Vivo</i> . <i>Cancer Research</i> , 2016, 76, 403-417.	0.9	57
13	Boosting ADCC and CDC activity by Fc engineering and evaluation of antibody effector functions. <i>Methods</i> , 2014, 65, 105-113.	3.8	56
14	A single-chain triplebody with specificity for CD19 and CD33 mediates effective lysis of mixed lineage leukemia cells by dual targeting. <i>MAbs</i> , 2011, 3, 21-30.	5.2	54
15	$\gamma\delta$ T cell activation by bispecific antibodies. <i>Cellular Immunology</i> , 2015, 296, 41-49.	3.0	54
16	Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. <i>Journal of Immunological Methods</i> , 2011, 373, 67-78.	1.4	47
17	Mimicking an Induced Self Phenotype by Coating Lymphomas with the NKp30 Ligand B7-H6 Promotes NK Cell Cytotoxicity. <i>Journal of Immunology</i> , 2012, 189, 5037-5046.	0.8	47
18	Characterization of a Mutated IgA2 Antibody of the m(1) Allotype against the Epidermal Growth Factor Receptor for the Recruitment of Monocytes and Macrophages. <i>Journal of Biological Chemistry</i> , 2012, 287, 25139-25150.	3.4	44

#	ARTICLE	IF	CITATIONS
19	Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cells. <i>Cancer Letters</i> , 2011, 303, 128-139.	7.2	42
20	Daratumumab eradicates minimal residual disease in a preclinical model of pediatric T-cell acute lymphoblastic leukemia. <i>Blood</i> , 2019, 134, 713-716.	1.4	42
21	Resistance of cyclooxygenase-2 expressing pancreatic ductal adenocarcinoma cells against $\hat{3}^1$ T cell cytotoxicity. <i>Onc Immunology</i> , 2015, 4, e988460.	4.6	41
22	The Fc-engineered CD19 antibody MOR208 (XmAb5574) induces natural killer cell-mediated lysis of acute lymphoblastic leukemia cells from pediatric and adult patients. <i>Leukemia</i> , 2013, 27, 1595-1598.	7.2	39
23	Monitoring Circulating $\hat{3}^3\hat{3}^1$ T Cells in Cancer Patients to Optimize $\hat{3}^3\hat{3}^1$ T Cell-Based Immunotherapy. <i>Frontiers in Immunology</i> , 2014, 5, 643.	4.8	34
24	Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study. <i>Haematologica</i> , 2015, 100, 541-547.	3.5	34
25	Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibodyâ€dependent cellâ€mediated cytotoxicity and complementâ€dependent cytotoxicity. <i>British Journal of Haematology</i> , 2018, 181, 413-417.	2.5	33
26	An Fc-engineered CD19 antibody eradicates MRD in patient-derived MLL-rearranged acute lymphoblastic leukemia xenografts. <i>Blood</i> , 2017, 130, 1543-1552.	1.4	32
27	Fusion proteins between ligands for NKG2D and CD20-directed single-chain variable fragments sensitize lymphoma cells for natural killer cell-mediated lysis and enhance antibody-dependent cellular cytotoxicity. <i>Leukemia</i> , 2012, 26, 830-834.	7.2	31
28	Oncogenic Deregulation of Cell Adhesion Molecules in Leukemia. <i>Cancers</i> , 2019, 11, 311.	3.7	30
29	A CD19-specific single-chain immunotoxin mediates potent apoptosis of B-lineage leukemic cells. <i>Leukemia</i> , 2007, 21, 1405-1412.	7.2	28
30	HER2 monoclonal antibodies that do not interfere with receptor heterodimerization-mediated signaling induce effective internalization and represent valuable components for rational antibody-drug conjugate design. <i>MAbs</i> , 2014, 6, 392-402.	5.2	28
31	Monitoring and functional characterization of the lymphocytic compartment in pancreatic ductal adenocarcinoma patients. <i>Pancreatology</i> , 2016, 16, 1069-1079.	1.1	28
32	An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated Cytotoxicity. <i>Transfusion Medicine and Hemotherapy</i> , 2017, 44, 292-300.	1.6	28
33	HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity. <i>Oncotarget</i> , 2015, 6, 32075-32088.	1.8	28
34	Enhancing natural killer cell-mediated lysis of lymphoma cells by combining therapeutic antibodies with CD20-specific immunoligands engaging NKG2D or NKp30. <i>Onc Immunology</i> , 2016, 5, e1058459.	4.6	26
35	Nitric oxide is synthesized in acute leukemia cells after exposure to phenolic antioxidants and initially protects against mitochondrial membrane depolarization. <i>Cancer Letters</i> , 2004, 215, 43-52.	7.2	25
36	An IgG3 switch variant of rituximab mediates enhanced complementâ€dependent cytotoxicity against tumour cells with low $\langle scp \rangle CD \langle /scp \rangle 20$ expression levels. <i>British Journal of Haematology</i> , 2013, 161, 282-286.	2.5	25

#	ARTICLE	IF	CITATIONS
37	CD20-specific Immunoligands Engaging NKG2D Enhance T Cell-Mediated Lysis of Lymphoma Cells. <i>Scandinavian Journal of Immunology</i> , 2017, 86, 196-206.	2.7	25
38	A recombinant triplebody with specificity for CD19 and HLA-DR mediates preferential binding to antigen double-positive cells by dual-targeting. <i>MAbs</i> , 2012, 4, 45-56.	5.2	24
39	Combining daratumumab with CD47 blockade prolongs survival in preclinical models of pediatric T-ALL. <i>Blood</i> , 2022, 140, 45-57.	1.4	22
40	Enhanced ADCC Activity of Affinity Maturated and Fc-Engineered Mini-Antibodies Directed against the AML Stem Cell Antigen CD96. <i>PLoS ONE</i> , 2012, 7, e42426.	2.5	21
41	The novel immunotoxin HM1.24-ETA induces apoptosis in multiple myeloma cells. <i>Blood Cancer Journal</i> , 2014, 4, e219-e219.	6.2	20
42	Human kappa light chain targeted Pseudomonas exotoxin A identifying human antibodies and Fab fragments with favorable characteristics for antibody-drug conjugate development. <i>Journal of Immunological Methods</i> , 2011, 371, 122-133.	1.4	19
43	Fc Engineering: Design, Expression, and Functional Characterization of Antibody Variants with Improved Effector Function. <i>Methods in Molecular Biology</i> , 2012, 907, 519-536.	0.9	19
44	Oncogenic KRAS Impairs EGFR Antibodies' Efficiency by C/EBP-Dependent Suppression of EGFR Expression. <i>Neoplasia</i> , 2012, 14, 190-IN7.	5.3	19
45	A single chain immunotoxin, targeting the melanoma-associated chondroitin sulfate proteoglycan, is a potent inducer of apoptosis in cultured human melanoma cells. <i>Melanoma Research</i> , 2008, 18, 73-84.	1.2	18
46	Effect of a tail piece cysteine deletion on biochemical and functional properties of an epidermal growth factor receptor-directed IgA2 m(1) antibody. <i>MAbs</i> , 2013, 5, 936-945.	5.2	16
47	Promoting natural killer cell functions by recombinant immunoligands mimicking an induced self phenotype. <i>Oncolmmunology</i> , 2013, 2, e24481.	4.6	15
48	Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering. <i>Antibodies</i> , 2020, 9, 63.	2.5	15
49	Immunotherapeutic targeting of activating natural killer cell receptors and their ligands in cancer. <i>Clinical and Experimental Immunology</i> , 2022, 209, 22-32.	2.6	14
50	A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor Cells. <i>Journal of Immunology</i> , 2015, 195, 5077-5087.	0.8	13
51	AFM26 is a novel, highly potent BCMA/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma. <i>Journal of Clinical Oncology</i> , 2017, 35, 8045-8045.	1.6	12
52	Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapy. <i>Haematologica</i> , 2020, 106, haematol.2020.251371.	3.5	11
53	Enhancement of epidermal growth factor receptor antibody tumor immunotherapy by glutaminyl cyclase inhibition to interfere with CD47/signal regulatory protein alpha interactions. <i>Cancer Science</i> , 2021, 112, 3029-3040.	3.9	11
54	The selection of variable regions affects effector mechanisms of IgA antibodies against CD20. <i>Blood Advances</i> , 2021, 5, 3807-3820.	5.2	9

#	ARTICLE	IF	CITATIONS
55	A novel Fc-engineered human ICAM-1/CD54 antibody with potent anti-myeloma activity developed by cellular panning of phage display libraries. <i>Oncotarget</i> , 2017, 8, 77552-77566.	1.8	9
56	An Fc-Engineered CD19 Antibody Engages Macrophages and Is Effective in Xenograft Models of Pediatric Acute Lymphoblastic Leukemia. <i>Blood</i> , 2016, 128, 277-277.	1.4	8
57	Perspectives of Fc engineered antibodies in CD19 targeting immunotherapies in pediatric B-cell precursor acute lymphoblastic leukemia. <i>Oncolmmunology</i> , 2018, 7, e1448331.	4.6	7
58	Fc Glyco- and Fc Protein-Engineering: Design of Antibody Variants with Improved ADCC and CDC Activity. <i>Methods in Molecular Biology</i> , 2018, 1827, 381-397.	0.9	7
59	Tumor cell lysis and synergistically enhanced antibody-dependent cell-mediated cytotoxicity by NKG2D engagement with a bispecific immunoligand targeting the HER2 antigen. <i>Biological Chemistry</i> , 2021, .	2.5	6
60	Engineering of CD19 Antibodies: A CD19-TRAIL Fusion Construct Specifically Induces Apoptosis in B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) Cells In Vivo. <i>Journal of Clinical Medicine</i> , 2021, 10, 2634.	2.4	5
61	Antibody-Dependent Cellular Cytotoxicity in Patients on Chronic Hemodialysis. <i>American Journal of Nephrology</i> , 2013, 38, 379-387.	3.1	4
62	Fc-optimized antibodies quickly pull the trigger. <i>Blood</i> , 2014, 124, 3180-3181.	1.4	3
63	Mouse Immune Libraries for the Generation of ScFv Fragments Directed Against Human Cell Surface Antigens. , 2010, , 47-63.		3
64	Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies by augmenting tumor cell phagocytosis. <i>Blood Advances</i> , 2022, 6, 4847-4858.	5.2	3
65	The novel multispecies Fc-specific <i>Pseudomonas</i> exotoxin A fusion protein $\hat{I}\pm$ -Fc-ETA $\hat{a}$ $\hat{e}$ $\hat{2}$ enables screening of antibodies for immunotoxin development. <i>Journal of Immunological Methods</i> , 2015, 418, 75-83.	1.4	2
66	Enhancing Cytokine-Induced Killer (CIK) cell activity with Her2-specific Fc-engineered antibodies and antibody derivatives. <i>European Journal of Cancer</i> , 2018, 92, S23-S24.	2.8	2
67	Targeting CD96 For Antibody Based Elimination Of Leukemic Stem Cells In AML: A New Strategy In Stem Cell Transplantation. <i>Blood</i> , 2013, 122, 3972-3972.	1.4	2
68	CD20 Antibodies of Human IgA Isotype Mediate CDC, and ADCC By Myeloid Effector Cells. <i>Blood</i> , 2016, 128, 1835-1835.	1.4	2
69	Mimicking An Induced Self Phenotype by Coating Lymphomas with the Nkp30-Ligand B7-H6 Promotes Antitumoral Natural Killer Cell Cytotoxicity. <i>Blood</i> , 2011, 118, 103-103.	1.4	2
70	Analyses of a Pair of Concordant Twins with Infant ALL and Discordant Clinical Outcome Reveals Immunescape As a Mechanism of Disease Persistence in MLL-Rearranged Leukemia. <i>Blood</i> , 2014, 124, 3791-3791.	1.4	2
71	Effector Cell Recruitment by Bispecific Antibodies. , 2011, , 217-241.		1
72	CD96 antibody TH-111 for detection of AML leukemic stem cells, and purging of autografts for stem cell transplantation.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7090-7090.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Blockade of CD47-SirpÎ± Interactions Improved Myeloid Effector Cell Mediated Lymphoma Cell Killing By the HLA-DR Antibody Apolizumab. <i>Blood</i> , 2019, 134, 5305-5305.	1.4	1
74	The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity <i>In Vitro</i> and <i>In Vivo</i>. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 70-78.	4.1	1
75	Blocking the Don't Eat Me Signal (CD47-SIRPÎ± Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma. <i>Blood</i> , 2021, 138, 2684-2684.	1.4	1
76	Engineered Antibody Derivatives in Preclinical and Clinical Development. , 2013, , 251-284.		0
77	CD96 Antibody TH-111 Eradicates AML-LSC from Autografts and the Fc- Engineered Variant MSH-TH111e May be Used In Vivo. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, S200.	2.0	0
78	Tricking the devil with an engineered protein switch for ex vivo blood cell production. <i>Cytherapy</i> , 2020, 22, S33.	0.7	0
79	The CD19 Antibody MOR208 Efficiently Triggers Natural Killer Cell-Mediated Cytotoxicity Against Acute Lymphoblastic Leukemia Cells From Pediatric and Adult Patients. <i>Blood</i> , 2012, 120, 1502-1502.	1.4	0
80	HM1.24/CD317-directed immunotoxin to eliminate malignant plasma cells in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2013, 31, 8604-8604.	1.6	0
81	Fc Engineering of Antibodies and Antibody Derivatives by Primary Sequence Alteration and Their Functional Characterization. <i>Methods in Molecular Biology</i> , 2014, 1131, 525-540.	0.9	0
82	Identification and activity of the novel antibody MSH-TP15 by a cell-based phage display screening approach.. <i>Journal of Clinical Oncology</i> , 2014, 32, e22156-e22156.	1.6	0
83	A Novel ICAM-1/CD54 Antibody Identified By Phage Display with Potent Pre-Clinical Anti-Myeloma Activity. <i>Blood</i> , 2014, 124, 2095-2095.	1.4	0
84	Enhancing Natural Killer Cell-Mediated Lysis of Lymphoma Cells By Combining Therapeutic Antibodies with CD20-Specific Immunoligands Engaging NKG2D or NKp30. <i>Blood</i> , 2014, 124, 1779-1779.	1.4	0
85	A novel human Fc-optimized ICAM-1/CD54 antibody (MSH-TP15e) with potent anti-myeloma activity in vitro and in vivo.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19533-e19533.	1.6	0
86	Anti-myeloma activity of the novel ADCC-optimized human CD54 (ICAM-1) antibody MSH-TP15e.. <i>Journal of Clinical Oncology</i> , 2016, 34, e14009-e14009.	1.6	0
87	The Novel ADCC-Optimized Human CD54 (ICAM-1) Antibody MSH-TP15e Has Potent Anti-Myeloma Activity. <i>Blood</i> , 2016, 128, 4471-4471.	1.4	0
88	Targeting CD38 in T-ALL using a novel Fc-engineered antibody. , 2018, 230, .		0
89	Venetoclax Enhances the Efficacy of Therapeutic Antibodies in B-Cell Malignancies. <i>Blood</i> , 2018, 132, 4177-4177.	1.4	0
90	Potent targeting of B cell lymphoma and plasma cell tumors by a tetravalent, Fc-engineered antibody directed against the glycoantigen CD75s.. <i>Journal of Clinical Oncology</i> , 2019, 37, e14004-e14004.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Venetoclax enhances the efficacy of therapeutic antibodies in B-cell malignancies. <i>Klinische Padiatrie</i> , 2019, 231, .	0.6	0
92	Immunotherapeutic co-targeting of CD38 and CD47 in T-cell acute lymphoblastic leukemia (T-ALL). , 2020, 232, .		0
93	Co-Targeting of CD38 and CD47 in T Cell Acute Lymphoblastic Leukemia. <i>Blood</i> , 2020, 136, 39-40.	1.4	0